Recursion Pharmaceuticals, Inc. Class A Common Stock RXRX
$4.36
+10.38%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 4 | FORM 4 | 2026-10-07 | View → |
| 4 | FORM 4 | 2026-10-07 | View → |
| 4 | FORM 4 | 2026-10-02 | View → |
| 4 | FORM 4 | 2026-10-02 | View → |
| 8-K | 8-K | 2026-09-21 | View → |
| 4 | FORM 4 | 2026-09-16 | View → |
| 4 | FORM 4 | 2026-09-10 | View → |
| 4 | FORM 4 | 2026-09-02 | View → |
| 4 | FORM 4 | 2026-08-18 | View → |
| 4 | FORM 4 | 2026-08-18 | View → |
| 4 | FORM 4 | 2026-08-18 | View → |
| 4 | FORM 4 | 2026-08-06 | View → |
| 10-Q | 10-Q | 2026-08-05 | View → |
| 8-K | 8-K | 2026-08-05 | View → |
| 4 | FORM 4 | 2026-07-09 | View → |
| 4 | FORM 4 | 2026-07-02 | View → |
| 4 | FORM 4 | 2026-07-02 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 4 | FORM 4 | 2026-06-22 | View → |
| 8-K | 8-K | 2026-06-18 | View → |
| 4 | FORM 4 | 2026-06-17 | View → |
| 4 | FORM 4 | 2026-06-05 | View → |
| 4 | FORM 4 | 2026-06-05 | View → |
| 4 | FORM 4 | 2026-06-04 | View → |
| 4 | FORM 4 | 2026-06-04 | View → |
| 4 | FORM 4 | 2026-05-27 | View → |
| 4 | FORM 4 | 2026-05-19 | View → |
| 4 | FORM 4 | 2026-05-19 | View → |
| 4 | FORM 4 | 2026-05-19 | View → |
| 4 | FORM 4 | 2026-05-19 | View → |
| 4 | FORM 4 | 2026-05-08 | View → |
| 4 | FORM 4 | 2026-05-07 | View → |
| 10-Q | 10-Q | 2026-05-06 | View → |
| 8-K | 8-K | 2026-05-06 | View → |
| DEF 14A | DEF 14A | 2026-04-30 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $4.36
- Market Cap
- $2.34 billion
- 52-Week Range
- $2.77 – $7.18
- Average Volume
- 24.55 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.